Eli Lilly & Co. (LLY.US) announced that its weight-loss drug called Zepbound outperformed competitor Novo Nordisk A/S' Wegovy (NOVOB.DK) in the first head-to-head study of the two drugs.
In the Lilly-sponsored study, people treated with Zepbound lost an average of 20% of their body weight in 72 weeks, while those receiving Wegovy lost 14%. The results confirm earlier studies of both drugs, which indicated a stronger effect of Zepbound. Full results will be published next year, Eli Lilly said. The official study document can be found here.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appImmediately following the announcement, Novo Nordisk shares lost 0.7% in value, while Eli Lily shares gained nearly 2% before the session began.
LLY shares gain before the opening of the session on Wall Street. Source: Yahoo Finance
Meanwhile, Novo Nordisk shares are bouncing off the resistance zone set by the 50-day EMA (blue curve) and losing nearly 1.2% today. Source: xStation
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
